Docket #: S19-500
Early diagnosis and treatment of eye cancer
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status. These biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, or monitoring treatment of eye cancer. The earlier identification of uveal melanoma will expedite the schedule of treatment and increase survival.
Related Technology:
S18-559 "Biomarkers Differentiate Types of Uveitis"
Stage of Development
Applications
- Early diagnosis and treatment of eye cancers
- Precision Health
Advantages
- Faster and more precise than current methods
- Point-of-care processing
- Uses proteomic platform analysis
- Earlier diagnosis and treatment will lead to better survival outcomes
Publications
- Velez G, Nguyen HV, Chemudupati T, Ludwig CA, Toral M, Reddy S, Mruthyunjaya P, Mahajan VB. Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Mol Cancer. 2021 Feb 24;20(1):39.
Related Links
Patents
- Published Application: WO2021155235
- Published Application: 20230152322
Similar Technologies
-
High quality factor phase gradient metasurfaces S19-429High quality factor phase gradient metasurfaces
-
NK-cell based therapies to treat MYC-driven lymphomas S17-367NK-cell based therapies to treat MYC-driven lymphomas
-
'?Dicer' for Uniformly Sectioning Tissue Samples S20-435'?Dicer' for Uniformly Sectioning Tissue Samples